A case of rapid desensitization for rituximab-induced delayed hypersensitivity reaction
10.4168/aard.2019.7.2.109
- Author:
Su Ho LEE
1
;
Jae Ha LEE
;
Nam Hee KIM
;
Dong Yoon KANG
;
Ju Yeun LEE
;
Soo Jie CHUNG
;
Ji Hyun OH
;
Hye Ryun KANG
Author Information
1. Wonkwang University College of Pharmacy, Iksan, Korea.
- Publication Type:Case Report
- Keywords:
Rituximab;
Delayed hypersensitivity;
Immunologic desensitization
- MeSH:
Aged;
B-Lymphocytes;
Desensitization, Immunologic;
Exanthema;
Humans;
Hypersensitivity;
Hypersensitivity, Delayed;
Hypersensitivity, Immediate;
Lymphoma, B-Cell;
Rituximab
- From:Allergy, Asthma & Respiratory Disease
2019;7(2):109-112
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Rituximab is a monoclonal antibody used for the treatment of B-cell malignancies, including diffuse large B-cell lymphoma. Infusion-related hypersensitivity reactions to rituximab is well known, and delayed hypersensitivity reactions to rituximab are also reported. Desensitization is commonly used to prevent immediate hypersensitivity reactions, but recently there have been cases of successful desensitization therapy for delayed hypersensitivity reactions. A 66-year-old patient who underwent rituximab treatment for diffuse large B-cell lymphoma showed repeated rituximab-induced delayed hypersensitivity reactions with whole body rashes. Intravenous rapid desensitization was performed by using a 1-bottle, 11-step protocol for 6 cycles and thereafter hypersensitivity reaction did not recur. We herein reported a case of delayed hypersensitivity reaction caused by rituximab, which was successfully desensitized using our 11-step protocol.
